Financial Performance - Telescope Innovations Corp. reported revenues of CAD 1.4 million for the fiscal quarter ended May 31, 2025, compared to CAD 1.2 million for the same quarter in FY 2024, reflecting a growth of approximately 14% [1][7] - The company incurred an adjusted EBITA loss of CAD 0.1 million, which is an increase from a loss of CAD 0.05 million in the comparable quarter of FY 2024 [1][7] - Total expenses for the quarter were CAD 1.9 million, up from CAD 1.4 million in the same quarter of FY 2024 [7] Operational Highlights - Telescope shipped its first battery-grade lithium sulfide (Li₂S) samples to major battery industry groups in Asia and North America, marking the initial customer evaluation of its proprietary low-temperature production process [4] - The company is part of the Arkansas Lithium Technology Accelerator, focusing on innovating the battery supply chain [4] - The DirectInject-LC™ product experienced significant growth, with sales and order pipelines more than doubling compared to Q3 2024 [7] Strategic Partnerships - Telescope is collaborating with Pfizer to develop a "Phase 1" Self-Driving Lab (SDL) platform, which aims to enhance chemistry research efficiency by up to 100 times compared to traditional methods [7] - The company is working with Mettler Toledo on a global distribution campaign, executing 11 application feasibility studies and participating in lead-generating events [7] Company Overview - Telescope Innovations Corp. focuses on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing advanced technologies such as robotic platforms and artificial intelligence [6]

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/Q2rTHfUQwO https://t.co/Q2rTHfUQwO ...

Industry Focus - Pharmaceutical cannabis is considered the biggest future for cannabis industry [1] - Ajna BioSciences, founded by Joel Stanley, has a botanical drug in the FDA pipeline [1] Company Information - Joel Stanley (with his brother Jared) is the founder of Ajna BioSciences [1] - Charlotte's Web provided the photo [1]

Group 1 - The article highlights significant announcements in the stock market from Sunday to Thursday, including "suspensions and resumption of trading, shareholding changes, investment wins, acquisitions, earnings reports, unlocks, and high transfers" [1] - Important announcements are marked in red to assist investors in identifying investment hotspots and preventing various black swan events, providing ample time for analysis and selection of suitable listed companies [1] - The article mentions a company that has achieved the supply of solid-state battery cathode materials in hundred-kilogram samples [1] Group 2 - Another company is noted for its services provided to certain military research institutes, integrating cloud computing, military industry, blockchain, robotics, AI, Huawei Harmony, and state-owned cloud [1] - A company in the innovative drug sector, particularly in weight loss drugs, is projected to have a net profit increase of over three times year-on-year in the first half of the year [1]

Innovation & R&D - The US leads the world in life science innovation due to a combination of factors including investment in basic research, venture capital, strong companies, and protection of intellectual property [3][5] - Big Pharma increasingly relies on external innovation, with internal drug development accounting for less than 30% of FDA approvals between 2015 and 2021 [11] - AI and machine learning are accelerating drug discovery by enabling the screening of 1.7 million compounds in approximately 5-10 days, significantly reducing the time required for identifying lead compounds [3][14][15] Investment & Finance - In 2021, the pharmaceutical industry invested over $80 billion annually in R&D, a tenfold increase over 10 years, representing approximately 25% of pharma companies' revenues [4] - Venture capital firms investing in biotech require patience, with a time horizon of 10-15 years to see a drug from discovery to commercialization [13] - New Jersey offers an R&D tax credit to attract big pharma companies and has a program allowing early-stage life sciences companies to monetize their net operating losses [20][21] Company Strategy & Focus - Johnson & Johnson (J&J) has invested $50 billion in R&D and M&A since the beginning of last year [10] - J&J actively scouts the world for promising innovations and technologies to leverage its scale in research, development, manufacturing, and commercialization [6] - J&J is developing an oral medicine, icotrokinra, to treat plaque psoriasis, which is expected to be a significant breakthrough and contribute to growth in the second half of the decade [7][9]

[Music] Bringing a life-saving drug to market requires analyzing massive amounts of complex data. The pharmaceutical industry needs a faster, more automated way to extract meaning and act on it. Ivia is using Agentic AI to do exactly that.Training AI agents to navigate more than a million data streams for clinical, medical, and commercial professionals. Its healthcare grade AI platform combines a growing set of AI agents, each designed to streamline how insights turn into action. Built with NVIDIA Neotron m ...

Financial Data and Key Metrics Changes - The company has grown margins by almost 400 basis points from 2018 to now and is on track to increase its margin profile by another 300 basis points over the next four years [22][23] - The company reaffirmed a revenue growth of 5% to 7% for Q3 and expects a margin profile of approximately 14% [75][76] Business Line Data and Key Metrics Changes - The advanced facilities and advanced manufacturing sectors, which include life sciences and semiconductor industries, represent about 25% of the company's business [40] - The industrial water space is at an inflection point, with significant growth potential due to increasing water scarcity and the need for treatment systems [47] Market Data and Key Metrics Changes - The private sector continues to move forward with capital projects, particularly in life sciences and chip manufacturing, despite uncertainties like tariffs [30][31] - State and local governments have not paused projects, continuing to utilize appropriated funds [33] - The federal sector, which represents about 9% of the business, has seen some pausing but is now starting to resume projects [34][35] Company Strategy and Development Direction - The company has redefined its asset life cycle approach, engaging earlier in clients' business to optimize capital and enhance project outcomes [17][18] - The company aims to increase its global delivery model from 10% of overall delivery to potentially doubling it in the next three to five years [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline for the pharma sector, driven by advancements in AI for drug discovery, which allows for faster R&D processes [68][69] - The company is optimistic about the future, citing strong secular tailwinds across various markets, including water, environmental, and advanced facilities [12][13] Other Important Information - The company has a diverse project portfolio with 29,000 engagements, reducing exposure to any single client [79] - The company is focusing on enhancing its tech platforms to improve efficiency and develop unique solutions for clients [82][83] Q&A Session Summary Question: How are customers responding to the current economic environment? - Management noted that private sector clients are moving forward with capital projects, while state and local governments continue to utilize appropriated funds without pausing projects [30][33] Question: What is the company's strategy regarding the global delivery model? - The company aims to increase its global delivery model from 10% to potentially doubling it in the next three to five years, emphasizing the importance of trust built over decades with clients [49][51] Question: How does the company plan to balance M&A, buybacks, and dividends? - Management indicated that in the near term, M&A is not a focus, and the company plans to continue returning a significant portion of free cash flow to shareholders while reinvesting in itself [86]

Jan Hatzius +1(212)902-0394 | jan.hatzius@gs.com Goldman Sachs & Co. LLC Alec Phillips +1(202)637-3746 | alec.phillips@gs.com Goldman Sachs & Co. LLC David Mericle +1(212)357-2619 | david.mericle@gs.com Goldman Sachs & Co. LLC Ronnie Walker +1(917)343-4543 | ronnie.walker@gs.com Goldman Sachs & Co. LLC 17 May 2025 | 10:29PM EDT US Daily: Tracking Trade with High-Frequency Data (Peng) Manuel Abecasis +1(212)902-8357 | manuel.abecasis@gs.com Goldman Sachs & Co. LLC Elsie Peng +1(212)357-3137 | elsie.peng@gs.c ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [5][20] - Gross profit rose by 53% to $4,600,000, representing 58.5% of total revenue, up from 56.2% a year ago, primarily due to increased manufacturing scale and improved yield [20][21] - Net loss for Q1 2025 was $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [21][22] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA, and recurring subscribers making up 90% of revenue [6][13] - The Amazon channel represented 20% of the business, with improvements in customer conversion and repeat purchase rates [6] - The company launched new products, including a superfood tea lineup and plans for a hydration beverage, targeting significant market segments [9][12][60] Market Data and Key Metrics Changes - The company is expanding its reach into new consumer segments and channels, including international shipping and social media platforms like TikTok [42][43] - The market for non-GMO, plant-based compounds is growing, with increasing consumer awareness of health benefits related to blood flow and longevity [8][79] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025, focusing on balancing growth with profitability [17][18] - Strategic investments will be made in expanding the direct-to-consumer portfolio, enhancing R&D processes, and building AI-powered tools for CDMO services [18] - The company is targeting a 20% adjusted EBITDA margin for its direct-to-consumer division and higher margins in the CDMO segment [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its growth strategy and deliver life-changing compounds, highlighting the synergy between the direct-to-consumer and CDMO divisions [23][70] - The company is optimistic about the increasing interest from pharmaceutical companies in its botanical synthesis technology, which offers consistent and economically viable compounds [70][71] Other Important Information - The company raised $3,900,000 in debt financing during the quarter, increasing cash and cash equivalents to $3,400,000 [22] - The company is preparing to launch the olivoboscoside cell product in 2026, targeting significant market opportunities in liver health and cholesterol management [13][79] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - Management explained that Phase two involves moving from solid media to liquid media for cell conditioning, with an expected timeline of six to nine months [27][28] Question: How long will it take to narrow down targets with Tate and Lyle? - Management indicated that significant work is underway, with a comprehensive update expected by the end of the year [30] Question: Should we expect continued gross margin expansion as revenue grows? - Management affirmed the intention to drive continued gross profit margin improvement alongside revenue growth [31][32] Question: How many products contributed to revenue in Q1, and how many are expected by year-end? - Management noted that three product lines contributed to Q1 revenue, with expectations to increase to four by Q2 and five by Q3 or Q4 [36][38] Question: Will marketing costs drop due to increased ad inventory? - Management highlighted efforts to reduce marketing costs as a percentage of revenue while exploring new channels for customer acquisition [39][44] Question: Does the second quarter guidance include contributions from the CDMO business? - Management confirmed that the guidance includes revenue recognition from existing CDMO projects and potential new catalysts [45][46] Question: How many CDMO programs can be run concurrently? - Management stated that the current capacity allows for five to seven concurrent projects in stage one [49] Question: What is the long-term opportunity for the beauty product? - Management discussed a focused strategy on high-margin categories, including health and beauty, with plans for a launch in Q1 next year [60][61]

Core Viewpoint - The upcoming 2025 China Industrial Transfer Development Matching Event in Sichuan represents a significant opportunity for the province to enhance its industrial capabilities and drive high-quality economic development [1] Industrial Development - Sichuan has been actively exploring high-quality industrial development, focusing on six key industries: electronic information, equipment manufacturing, food and textiles, energy and chemicals, advanced materials, and pharmaceutical health, which form the backbone of its industrial economy [1][4] - In the first quarter of this year, the province's industrial added value above designated size grew by 7.2% year-on-year, with 33 out of 41 major industrial categories showing growth, indicating a robust industrial development momentum [1][4] Policy Support - In 2023, Sichuan introduced the "Action Plan for Quality Improvement and Doubling of Six Key Industries (2022-2027)," targeting 20 clusters and 50 industrial chains to create national and world-class manufacturing clusters [4][10] - The provincial government has committed to implementing ten support policies to advance the quality improvement of these six key industries [4][10] Digital Transformation - Sichuan has launched a comprehensive "Smart Transformation and Digital Upgrade" initiative, with 95 key tasks aimed at guiding enterprises in their transformation efforts [7][8] - By the end of last year, over 400 key projects had received support, leveraging more than 56 billion yuan in social investment and leading to the establishment of over 1,200 digital workshops [8][9] Emerging Industries - Sichuan is also focusing on emerging and future industries such as artificial intelligence, biotechnology, and drone technology, which are becoming significant drivers of economic growth [10][13] - The province has outlined 25 new industrial tracks in its "Action Plan for Competing in New Industrial Tracks (2023-2027)," emphasizing support for strategic emerging industries [10][11] Future Goals - By 2027, Sichuan aims to establish six trillion-yuan industries to support the construction of a modern industrial system [9][14] - The province is actively planning for future industries like 6G and quantum technology, aiming to cultivate new business models and industries [13][14]